Background {#Sec1}
==========

Soft tissue neck and shoulder musculoskeletal disorders (MSDs), namely, disorders of the muscles, tendons, ligaments, nerves, or blood vessels, are prevalent worldwide \[[@CR1]--[@CR4]\], are a common cause of work absence and disability \[[@CR5]\], and impose a sizeable societal economic burden \[[@CR1], [@CR3], [@CR4], [@CR6]--[@CR11]\].

Most options for screening, surveillance and diagnosis of proximal upper extremity MSDs depend on symptoms. Improved diagnostic and screening methods, especially objective techniques, are needed \[[@CR12], [@CR13]\]. A biomarker has been defined as "a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention"\[[@CR14]\]. Quantitative medical imaging techniques are increasingly used in clinical practice and MSD research, and enable detection of potential MSD biomarkers, including functional and morphological changes. The Quantitative Imaging Biomarkers Alliance and the Terminology Working Group define a quantitative imaging biomarker as "an objective characteristic derived from an in vivo image measured on a ratio or interval scale as an indicator of normal biological processes, pathogenic processes or a response to a therapeutic intervention" \[[@CR15]\]. Valid and reliable biomarkers could improve diagnosis and screening methods \[[@CR16]\] and provide objective means to evaluate medical treatments and workplace interventions. Use of such biomarkers may also elucidate MSD pathomechanisms.

Three biomarkers classes are conventionally described: exposure, effect (disease), and susceptibility \[[@CR17]\]. Herein, we have reviewed biomarkers of effect, defined as "any change that is qualitatively or quantitatively predictive of health impairment or potential impairment..." \[[@CR17]\]. Through measurement of biomarkers of effect, pathophysiological processes may be illuminated and used to stage MSD severity, such as early biomarkers that precede disease diagnosis versus late biomarkers in already diagnosed subjects.

Previous biomarker reviews {#Sec2}
--------------------------

Prior reviews on this topic include a pioneering paper highlighting the potential for MSD biomarkers to detect subclinical disease and monitor MSD severity \[[@CR18]\], and a later MSD review article \[[@CR19]\] focused on biochemical markers. Neither paper mentioned medical imaging. Our recent systematic review also focused on biochemical biomarkers in MSDs \[[@CR20]\]. To our knowledge, there have been no published reviews of quantitative imaging biomarkers in neck and shoulder MSDs.

The purpose of this systematic review was to conduct a comprehensive assessment of quantitative imaging biomarkers in neck and shoulder MSDs. We aimed to answer the following two research questions:Are there quantitative imaging biomarkers associated with the presence of neck and shoulder MSDs?Are there quantitative imaging biomarkers associated with the severity of neck and shoulder MSDs?

Methods {#Sec3}
=======

*Review team and process overview.* Our review team consisted of eight researchers with expertise in musculoskeletal radiology and in epidemiologic, intervention and experimental studies, including studies on pathomechanisms within the field of work-related MSD research. The review process was as follows: 1) research questions were formulated; 2) principal concepts of the review were defined; 3) a search strategy and terms were developed (Additional file [1](#MOESM1){ref-type="media"}); 4) PubMed and Scopus databases were searched, with results pooled with articles identified from the authors' files; 5) identified papers were screened based on pre-defined criteria (Additional files [1](#MOESM1){ref-type="media"}, [2](#MOESM2){ref-type="media"} and [3](#MOESM3){ref-type="media"}) using a two-step procedure of primary (title and abstract) and secondary (quality) screens; 6) summary tables were created from sufficient quality papers; and 7) evidence was synthesized with respect to the two research questions. A consensus process was used throughout the review process. See Gold et al. for further details \[[@CR20]\].

*Neck and shoulder MSDs* were defined as clinical diagnoses or musculoskeletal symptoms in the neck and shoulder region. These included both specific and non-specific conditions related to muscles, tendons, nerves, blood vessels or ligaments \[[@CR21]\]. The scope of this review encompassed MSDs that occur in a work-related context \[[@CR22]\].

*Quantitative imaging biomarker* was defined as an objective characteristic derived from an in vivo image or from an in vivo signal captured in response to electromagnetic radiation to detect morphology or function, measured on a ratio or interval scale as an indicator of normal biological or pathogenic processes \[[@CR15]\]. We have focused on minimally invasive/non-invasive methods. Potential quantitative imaging biomarkers could be derived through MRI, ultrasound, far infrared thermography, near infrared spectroscopy (NIRS), laser Doppler flowmetry, and other modalities. Thus, for example, muscle oxygenation as measured through NIRS was included in this review. Because plain radiographs (x-rays) are best utilized in evaluating bone abnormalities and have poor contrast resolution, this imaging modality is not routinely indicated in soft tissue evaluation \[[@CR23]--[@CR26]\]. Thus, studies using only plain radiography were excluded from this review.

*Severity* was operationalized as encompassing longitudinal and cross-sectional differences in symptoms.

*Inclusion criteria.* The current review was limited to studies on adults (age \> 18 years) with non-traumatic neck and shoulder MSDs, published between June 4, 1988 and October 14, 2016 and written in English language. Potential biomarkers were examined for the following specific MSDs, as categorized by Boocock, et al. \[[@CR21]\]: rotator cuff syndrome/shoulder tendonitis, shoulder capsulitis and thoracic outlet syndrome. Other specific MSDs included are listed in Boocock, et al. \[[@CR21]\] Table [2](#Tab2){ref-type="table"}, although status post-whiplash, cervico-brachial fibromyalgia, and joint-related conditions were excluded. Upper extremity non-specific regional pain, namely, "neck pain", "shoulder pain", and "neck/shoulder pain", was also included. We included articles that met our inclusion criteria, even if some parts of the study were consistent with the exclusion criteria; however, only results in compliance with our criteria were included.

*Exclusion criteria* are summarized in Additional file [2](#MOESM2){ref-type="media"}.

Literature search {#Sec4}
-----------------

The search was first conducted in PubMed and combined with articles identified from the authors' files. Articles were screened for quality. If met, a second search for papers that cited the sufficient quality articles was conducted using Scopus. Additional file [1](#MOESM1){ref-type="media"} provides an overview of the search strategy, while Fig. [1](#Fig1){ref-type="fig"} illustrates the overall search strategy and selection procedure. PubMed search terms included both MESH terms and key words selected for two categories: neck and shoulder MSDs, and biomarkers. Search terms within each category were combined using the "OR" operator, while search terms between categories were combined using "AND". A systematic procedure was carried out for selection of appropriate MESH terms and key words, where each search term was entered by a step-wise procedure. Fifteen articles were identified by the review team and used for refining the search and testing its sensitivity. See Additional file [4](#MOESM4){ref-type="media"} for the search string.Fig. 1Flowchart of literature search

A total of 4002 articles were examined by members of the review team. The final PubMed search resulted in 3999 articles; three additional papers were added from the team members' personal files. Primary and secondary screens were implemented (see below and Additional files [1](#MOESM1){ref-type="media"}, [2](#MOESM2){ref-type="media"} and [3](#MOESM3){ref-type="media"}). The Scopus search identified recently published articles in PubMed that still lacked assigned MESH terms. Since a PubMed search may miss relevant studies in other databases, the Scopus search reduced this potential search strategy bias. To assure clarity and limit reviewer bias, pilot testing of evaluation criteria was conducted at each stage of the review process.

Primary screen-selection of articles {#Sec100}
------------------------------------

The primary screen was conducted by two independent reviewers assessing each title and abstract for eligibility based on inclusion and exclusion criteria (Additional file [2](#MOESM2){ref-type="media"}), after importing all records from PubMed into systematic review software (EPPI-reviewer4 v4.3.4, EPPI-Centre, Social Science Research Unit, Institute of Education, University of London, UK). The full text was read if necessary. A "yes" answer on any question in Additional file [2](#MOESM2){ref-type="media"} resulted in article exclusion. Results were compared between reviewers, and consensus agreement was reached in all cases (with input from a third person in case of disagreement between reviewers). The same procedure was repeated for articles from personal files and articles found in Scopus.

Secondary screen-quality assessment and data extraction {#Sec5}
-------------------------------------------------------

All articles passing the primary screen were scored for quality by five review team members. The articles were randomly allocated to five different clusters; each reviewer was assigned randomly to two of these clusters. In the quality screen, each article was assessed by two independent reviewers, scores were compared, and a consensus agreement was reached after discussing disagreements (using a third reviewer as needed). Additional file [3](#MOESM3){ref-type="media"} lists questions used for the quality assessment. These questions were derived from reporting guidelines and checklists for quality assessment in health-related research studies \[[@CR27]--[@CR31]\]. Seventeen items were included in the scoring system, with each item scored as either "yes" (1 point), "unknown or not applicable" (0) or "no" (0). Scores were summed for each paper (range: 0--17). Articles scoring at or above 70% of the maximum (12/17) were labeled as "sufficient quality" and were included for data extraction. Articles scoring "no" on question 15 were excluded from data extraction. These included papers with less than appropriate statistical analysis methods, such as multiple comparisons without adjustment, and modeling without accounting for repeated measures. Data extraction items are listed in Additional file [5](#MOESM5){ref-type="media"}.

Research synthesis {#Sec6}
------------------

Ulitizing a best evidence synthesis approach, we evaluated the number of sufficient quality articles in order to identify a particular biomarker or class of biomarkers in their potential association with MSD(s) \[[@CR32]\]. Considering the biomarker heterogeneity, it was not possible to conduct a meta-analysis. However, it was possible to group results according to the MSD, and then by physiological process or morphology, e.g., hemodynamic and/or oxygenation indicators or muscle dimensions, within diagnoses or symptom designations. An association between a biomarker and an MSD in three or more sufficient quality studies (and at most one sufficient quality study with a null finding) was regarded as evidence that an indicator could serve as a MSD quantitative imaging biomarker. We did not design our review to present different levels of evidence.

Results {#Sec7}
=======

Of the 3999 articles identified through the PubMed (primary) search (Fig. [1](#Fig1){ref-type="fig"}), and the three papers added from authors' files, 99 met secondary screening criteria. Ten papers were excluded after reading the entire article, and three eliminated due to inadequate statistical methods, leaving 86 articles to be scored in the secondary (quality) screen. Forty-four of these met the sufficient quality criteria score. The Scopus database search of these 44 sufficient quality papers yielded 394 citations of which 26 were determined to be non-duplicates and relevant through title and abstract review. Seventeen were eliminated at the secondary screening stage after reading the entire article. Nine articles were scored during the secondary screen, although one was eliminated from data extraction for less than appropriate statistical methods. Of the remaining Scopus identified articles, five scored at ≥12. These five were added to the 44 PubMed identified and similarly scored articles. Thus, 49 studies were regarded to be of sufficient quality for data extraction.

Secondary screen-quality assessment overview {#Sec8}
--------------------------------------------

Additional file [6](#MOESM6){ref-type="media"} shows quality scores of all papers that had undergone secondary screening (*n* = 96; 86 from PubMed and 9 from Scopus). The majority had clearly defined aims, biomarkers, MSDs, and results. All but two unique studies (one longitudinal cohort represented by \[[@CR33]--[@CR35]\] and the other by \[[@CR36]\]) had a cross-sectional design, and most utilized convenience samplings of patients, for both cases and referents. Just over half of the studies controlled for confounding factors through exclusion to a particular age or gender, or through a statistical adjustment in the analysis. Thirty-four studies (37%) explicitly stated that those analyzing biomarkers were blinded to case status.

Data extraction from sufficient quality studies {#Sec9}
-----------------------------------------------

Additional file [7](#MOESM7){ref-type="media"} gives a descriptive overview of the included studies. The bulk of sufficient quality studies examined neck pain, rotator cuff tears, and trapezius myalgia and other neck/shoulder pain conditions. No sufficient quality studies examined thoracic outlet syndrome. Approximately three-quarters (19/25) of the shoulder disorder studies were conducted in populations with at least one analysis group having an average age of ≥50 years. In contrast, the mean age by analysis groups in the neck pain studies ranged from 22 to 34 years, while the mean age in neck/shoulder studies ranged from 23 to 48 years.

Are there quantitative imaging biomarkers associated with the presence of neck and shoulder MSDs? {#Sec10}
-------------------------------------------------------------------------------------------------

The majority of studies demonstrated an association between at least one biomarker and the MSD(s) examined (Table [1](#Tab1){ref-type="table"}). Only 9/49 (18%) studies reported insignificant findings throughout \[[@CR37]--[@CR45]\].Table 1Are there quantitative imaging biomarkers associated with the presence of neck and shoulder MSDs?MSD Classification and diagnosisAuthor(s)Major results (case-control comparison)ConclusionNeck disorders and symptoms Neck painDibai Filho (2012) \[[@CR37]\]Skin temperature\
Skin temperature (L & R trapezius), difference btwn sides (thermal asymmetry), NS.No Neck painElliott (2008) \[[@CR46]\]Fat index indicating fatty infiltration (relative fat)\
Fat index: cases \< controls, *p* \< 0.001 in all muscles.Yes\
↓ fat index in cases in all neck extensor muscles (see Additional file [7](#MOESM7){ref-type="media"}). Neck painFalla (2004) \[[@CR38]\]Subcutaneous tissue thickness over SCM, AS\
SCM subcutaneous tissue thickness (L & R): NS cases vs. controls\
AS subcutaneous tissue thickness (L & R): NS cases vs. controlsNo Neck painFernández-de-las-Peñas (2008) \[[@CR47]\]Multifidus CSA, muscle shape ratio\
CSA: ANOVA, group (*p* \< 0.001) & cervical level (*p* \< 0.001) effects. No interactions. Cases \< controls at C3, C4, C5 (*p* \< 0.001) & at C6 (*p* \< 0.01). Muscle shape ratio: ANOVA, group (*p* \< 0.001) & cervical level (*p* \< 0.001) effects. Significant interactions btwn group & level (*p* = 0.01). Cases \> controls at C3 (*p* \< 0.001) & C6 (*p* \< 0.01).Yes\
↓ multifidus CSA in cases at C3, C4, C5, C6\
↑ muscle shape ratio in cases at C3, C6 Neck painJavanshir (2011) \[[@CR48]\]Lco CSA, anterior-posterior dimension (APD), lateral dimension (LD), and shape ratio (LD/APD)\
Lco CSA: cases \< controls, *p* \< 0.001.\
Lco APD: cases \< controls, *p* \< 0.01.\
Lco LD, shape ratio, NS cases vs. controls.Yes\
↓ Lco CSA in cases\
↓ Lco APD in cases Neck painKarimi (2016) \[[@CR53]\]Dorsal neck muscle thickness change w. 50% & 100% shoulder MVC in 6 directions\
Dorsal neck muscle thickness: During MVC: significant interaction of group x muscle, *p* = 0.008. NS, cases vs. controls group x direction; group x force.Yes\
Dorsal neck muscle thickness group x muscle effect Neck painJesus-Moraleida (2011) \[[@CR49]\]Lco thickness, SCM thickness, change of thickness during test/thickness during rest = proportion of muscle recruitment\
Lco thickness increase throughout all CCFT phases: cases \< controls (*p* \< 0.001). SCM thickness increase throughout all CCFT phases: NS, cases vs. controls. Lco recruitment: cases \< controls, phase 4 (*p* = 0.02), phase 5 (*p* = 0.004), NS other phases. SCM recruitment: NS, cases vs. controls.Yes\
↓ Lco thickness increase throughout all CCFT phases in cases\
↓ Lco recruitment, phases 4 & 5 Neck painPark (2013) \[[@CR50]\]Mean difference in the bilateral semispinalis capitis muscle thickness\
Mean difference in the bilateral semispinalis capitis thickness: cases \> controls, *p* \< 0.05. Within cases mean difference in the bilateral semispinalis capitis thickness: painful side \< asymptomatic side, *p* \< 0.05.Yes\
↑ mean difference in the bilateral semispinalis capitis thickness in cases\
↓ mean difference in the bilateral semispinalis capitis thickness in painful side Neck painRahnama (2015) \[[@CR52]\]Multifidus muscle thickness change w. shoulder MVC in 6 directions\
Multifidus muscle thickness: baseline: NS, cases vs. controls;\
During MVC: significant interaction of group x force, controls \> cases (*p* = 0.03). NS, cases vs. controls group x direction; 3- & 4-way interactions involving group.Yes\
↓ multifidus muscle thickness increase in cases during isometric MVC Neck painSheard\
(2012) \[[@CR51]\]Differences in water relaxation values (T2 relaxation) quantified from scans before and after exercise were calculated (T2 shift) as a measure of SA muscle activity\
T2 shift: significant effect for level (*p* = .03) and significant group × level interaction (*p* = .04) but no significant main effect for group (*p* = .59). Post hoc T2 shift: cases \> controls at the T6 level (*P* = .02) only.Yes\
↑ T2 shift at T6 in casesShoulder disorders and symptoms Degenerative rotator cuff lesionBiberthaler (2003) \[[@CR54]\]Mean functional capillary density, mean capillary diameterMean functional capillary density: lesion \< control tissue (*p* \< 0.05). Mean capillary diameter: NS, lesion vs. control tissue (*p* \> 0.05).Yes\
↓ mean functional capillary density in lesion tissue Rotator cuff tear (full thickness)Chang (2014) \[[@CR56]\]Biceps long tendon (BLT) width, thickness, flattening ratio (width/thickness), cross-sectional area, echogenicity ratio\
BLT width, echogenicity ratio: NS, cases vs. controls\
BLT thickness: cases \> controls, *p* \< 0.01.\
BLT flattening ratio: cases \< controls, *p* \< 0.01.\
BLT cross-sectional area: cases \> controls, *p* \< 0.01.Yes\
↑ BLT thickness in cases\
↓ BLT flattening ratio in cases\
↑ BLT cross-sectional area in cases Rotator cuff tearChoo (2014) \[[@CR57]\]Rotator cable thickness, width\
Rotator cable thickness: difference among 4 groups (see shoulder tendinosis - Choo), *p* \< 0.001; post-hoc analysis -- full-thickness tear \> normal, *p* \< 0.001.\
Rotator cable width: difference among 4 groups (see shoulder tendinosis - Choo), *p* \< 0.001; post-hoc analysis -- full-thickness tear \> normal, *p* \< 0.001; partial-thickness tear \> normal^a^.Yes\
↑ rotator cable thickness in full-thickness tears\
↑ rotator cable width in full-thickness tears\
Perhaps\
↑ rotator cable width in partial-thickness tears Rotator cuff tearFunakoshi (2010) \[[@CR55]\]Vascularity in 4 ROIs: articular & bursal sides of supraspinatus tendon, medial & lateral sides of bursa\
Non-injected side: cases (RCT) \< controls, *p* \< 0.0001, in articular & bursal side of the supraspinatus tendon. Injected side: cases (contralateral to RCT) \< controls, *p* \< 0.0001, in articular & bursal side of the supraspinatus tendon. Cases vs. controls, NS, in medial and lateral side of bursa.Perhaps\
↓ vascularity in articular & bursal sides of supraspinatus in non-injected (rotator cuff tear) side in cases, but may be attributed to age.\
↓ vascularity in articular & bursal sides of supraspinatus in injected (rotator cuff intact) side in cases, but may be attributed to age. Rotator cuff tearHirano (2006) \[[@CR39]\]Full vs. partial rotator cuff tear, rotator cuff tear length, amount of subacrominal-subdeltoid bursal fluid\
Proportion of full & partial tears, NS.\
Proportion in categorical size of tears, NS.\
amount of subacrominal-subdeltoid bursal fluid, NS .No Rotator cuff tearKarthikeyan (2015) \[[@CR58]\]Total blood flow in 4 supraspinatus zones, in anteromedial zone, in posteromedial zone\
Total blood flow in 4 supraspinatus zones: cases (including shoulder impingement -- see below) \< controls, *p* = 0.001.\
Anteromedial supraspinatus zone: full-thickness tears \< controls, *p* = 0.02; partial-thickness tears vs. controls, NS.\
Posteromedial supraspinatus zone: full-thickness tears \< controls, *p* = 0.04; partial-thickness tears vs. controls, NS.Yes\
↓ supraspinatus blood flow in cases\
↓ anteromedial supraspinatus blood flow in full-thickness tears\
↓ posteromedial supraspinatus blood flow in full-thickness tears Rotator cuff tear (full-thickness)Keener (2015) \[[@CR35]\]Baseline rotator cuff tear width; Width enlargement (defined as ≥ 5 mm compared with that at baseline) percentage\
Baseline rotator cuff tear width: rotator cuff tear with anterior supraspinatus cable disruption \> rotator cuff tear with anterior supraspinatus cable intact, *p* \< 0.0001.\
Width enlargement percentage: NS, rotator cuff tear with anterior supraspinatus cable disruption vs. rotator cuff tear with anterior supraspinatus cable intact .Yes\
↑ baseline rotator cuff tear width with anterior supraspinatus cable disruption. Rotator cuff tearMall\
(2010) \[[@CR33]\]Rotator cuff tear length, tear width, tear area, rate of substantial tear progression (transformation of a partial-thickness tear into a full-thickness tear or a size increase of \> 5 mm in either the width or the length of a full thickness tear compared with that at the time of enrollment)\
Time of enrollment:\
full-thickness tear width: symptomatic \> asymptomatic, *p* = 0.02;\
tear length, tear area, NS.\
Change between visit 1 & visit 2 (see paper for definitions):\
Shoulder remained asymptomatic:\
NS, tear length, width, area.\
Shoulder became symptomatic:\
tear length: visit 2 \> visit 1, *p* = 0.008.\
tear width: visit 2 \> visit 1, *p* = 0.01 tear area: visit 2 \> visit 1, *p* = 0.006.\
Rate of substantial tear progression: symptomatic \> asymptomatic, *p* \< 0.01Yes\
↑ full-thickness tear width at enrollment in those who later became symptomatic in asymptomatic shoulder.\
↑ tear length, width, & area at visit 2 vs. at visit 1 in those who became symptomatic in asymptomatic shoulder.\
↑ rate substantial tear progression in in those who became symptomatic in asymptomatic shoulder. Rotator cuff tearMoosmayer (2013) \[[@CR36]\]Rotator cuff tear size in anteroposterior plane, in mediolateral plane, tear size increase in anteroposterior plane, in mediolateral plane.\
Rotator cuff tear size in anteroposterior plane: baseline: NS, symptomatic vs. asymptomatic; 3-year follow-up: symptomatic \> asymptomatic, *p* = 0.02\
Rotator cuff tear size in mediolateral plane: baseline: NS, symptomatic vs. asymptomatic; 3-year follow-up: NS, symptomatic vs. asymptomatic.\
Tear size increase in anteroposterior plane: NS, symptomatic vs. asymptomatic.\
Tear size increase in mediolateral plane: NS, symptomatic vs. asymptomatic.Yes\
↑ rotator cuff tear size in anteroposterior plane at follow-up in tears that became symptomatic Rotator cuff tear (partial & full) or rotator cuff diseaseKeener (2015) \[[@CR34]\]Rotator cuff tear enlargement (see paper for definition)\
Tear enlargement in 49%; median time to enlargement = 2.8 yrs. tear enlargement: assoc. w. final tear type, *p* \< 0.05: full vs. control, HR = 4.17; partial vs. control, HR = 2.73; full vs. partial, HR = 1.53 (all *p* \< 0.05, no CI given).\
New shoulder pain in 46%; median time to pain = 2.6 yrs. shoulder pain assoc. w. final tear type, *p* \< 0.05. Assoc. w. tear enlargement, HR = 1.66, *p* \< 0.05. 63% became painful before or at tear enlargement; 22% became painful later.Yes\
↑ risk tear enlargement in full-tears vs. controls, in partial tears vs controls, in full-tears vs. partial tears.\
↑ risk new shoulder pain w. tear enlargement. Rotator cuff tearTerabayashi (2014) \[[@CR59]\]Difference in blood flow peak systolic velocity (PSV), resistance index (RI) between sides\
Difference between sides in PSV in BA: NS, in any group.\
Difference between sides in PSV in AHCA: affected \> unaffected side in rotator cuff tear with night pain, *p* \< 0.001. NS, other groups.\
Difference between sides in RI in BA: NS, in any group.\
Difference between sides in RI in AHCA: affected \< unaffected side in rotator cuff tear with night pain, *p* \< 0.01.Yes\
↑ PSV in AHCA in affected vs unaffected side in rotator cuff tear with night pain.\
↓ RI in AHCA in affected vs unaffected side in rotator cuff tear with night pain. Supraspinatus tendinopathyArend (2014) \[[@CR63]\]Maximal supraspinatus tendon thickness (MSTT)\
MSTT: cases \> controls, *p* \< 0.05Yes\
↑ MSTT in cases Rotator cuff tendinitisCay (2012) \[[@CR60]\]Subacromial distance, humeral head diameter, Glenoid APD, glenoid articular surface diameter\
Sagittal subacromial distance: cases \< controls, *p* \< 0.001\
humeral head diameter, glenoid APD, axial glenoid/humerus, and axial glenoid minus humerus, NS in cases vs controls.\
coronal diameter of humerus: cases \< controls, *p* = 0.02.\
coronal glenoid/humerus, coronal glenoid minus humerus: NS in cases vs controls.Yes\
↓ sagittal subacromial distance in cases\
↓ coronal diameter of humerus in cases Rotator cuff tendinosisChoo (2014) \[[@CR57]\]Rotator cable thickness, width\
Rotator cable thickness: difference among 4 groups (see rotator cuff tear - Choo), *p* \< 0.001; post-hoc analysis -- NS, tendinosis vs controls. Rotator cable width: difference among 4 groups (see rotator cuff tear - Choo), *p* \< 0.001; post-hoc analysis -- tendinosis \> normal, *p* \< 0.05^a^.Perhaps\
↑ rotator cable width in tendinosis Rotator cuff tendinitisRechardt (2010) \[[@CR61]\]Carotid artery intima-media thickness\
Carotid artery imtima-media thickness: NS, in males and females.No Shoulder tendinopathyJoensen (2009) \[[@CR62]\]Supraspinatus tendon thickness\
Tendon thickness: symptomatic side \> asymptomatic side, *p* \< 0.01.Yes\
↑ tendon thickness in symptomatic side Frozen shoulder (Adhesive capsulitis)Li (2011) \[[@CR64]\]CHL thickness\
CHL thickness: cases \> controls, *p* \< 0.001.Yes\
↑ CHL thickness in cases Frozen shoulder (Adhesive capsulitis)Michelin (2013) \[[@CR67]\]Joint capsule thickness\
Joint capsule thickness: cases \> controls, *p* \< 0.0001Yes\
↑ joint capsule thickness in cases Frozen shoulder (Adhesive capsulitis)Song (2011) \[[@CR65]\]Joint capsule thickness in the axillary recess, enhancing portion of the axillary recess thickness, rotator interval thickness\
Axillary recess: Joint capsule thickness: cases \> controls, *p* \< 0.001.\
Axillary recess enhancing portion thickness: cases \> controls, *p* \< 0.001.\
Rotator interval Enhancing portion thickness cases \> controls, *p* \< 0.001.Yes\
↑ axillary recess joint capsule thickness in cases\
↑ Axillary recess enhancing portion thickness in cases\
↑ Rotator interval Enhancing portion thickness in cases Frozen shoulder (Adhesive capsulitisZhao (2012) \[[@CR66]\]CHL thickness, articular capsule thickness\
CHL thickness: cases \> controls, *p* \< 0.001 .\
articular capsule thickness: cases \> controls, *p* \< 0.05.Yes\
↑ CHL thickness in cases\
↑ articular capsule thickness in cases Shoulder impingement syndromeDaghir (2011) \[[@CR71]\]Subacromial-subdeltoid bursal thickness Greatest thickness in any view: NS cases vs. controls. Thickness in shortaxis supraspinatus view: cases \> controls, *p* = 0.0009. Thickness in long-axis supraspinatus view: NS cases vs. controls.Thickness in long-axis subscapularis view: NS cases vs. controls.Yes\
↑ subacromial-subdeltoid bursal thickness in cases on shortaxis supraspinatus view Shoulder impingement syndromeHébert (2003) \[[@CR68]\]AHD\
Cases vs. contralateral control:\
Flexion: main effect of group, *p* \< 0.01, and no interaction with position. Post hoc comparisons: cases \< controls at 70, 90, 110 & 130 degrees, *p* \< 0.01.\
Abduction: main effect of group, *p* \< 0.01, no interaction with position. Post hoc comparisons: cases \< controls at 80, 90, *p* \< 0.05 and 110 degrees, *p* \< 0.01.\
Cases vs. contralateral control vs. asymptomatic controls:\
Flexion - main effect of group, *p* \< 0.0001, (position effect, *p* \< 0.0001) interaction with position, *p* = 0.01. Post hoc comparisons: cases \< asymptomatic controls at 90 & 110 degrees, *p* \< 0.01. NS contralateral control vs asymptomatic controls, all positions.\
Abduction - main effect of group, *p* = 0.052. Post hoc comparisons: cases \< asymptomatic controls at 90 & 110 degrees, *p* \< 0.01. NS contralateral control vs asymptomatic controls, all positions.Yes\
↓ AHD in cases at 70, 90, 110, 130 degrees flexion vs. contralateral control\
↓ AHD in cases at 80, 90, 110 degrees abduction vs. contralateral control\
↓ AHD in cases at 90, 110 degrees flexion vs. asymptomatic controls\
↓ AHD in cases at in 90, 110 degrees abduction vs. asymptomatic controls Shoulder impingement syndromeKarthikeyan (2015) \[[@CR58]\]Total blood flow in 4 supraspinatus zones, in anteromedial zone, in posteromedial zone\
Total blood flow in 4 supraspinatus zones: cases (including rotator cuff tears -- see above) \< controls, *p* = 0.001.\
Anteromedial supraspinatus zone: shoulder impingement \< controls, *p* = 0.01.\
Posteromedial supraspinatus zone: shoulder impingement \< controls, *p* = 0.03.Yes\
↓ supraspinatus blood flow in cases\
↓ anteromedial supraspinatus blood flow in cases\
↓ posteromedial supraspinatus blood flow in cases Shoulder impingement syndromeLeong (2012) \[[@CR69]\]AHD, supraspinatus tendon thickness\
AHD: NS group effect, *p* = 0.08\
Supraspinatus tendon thickness: group effect, *p* = 0.002, post-hoc analysis: control volleyball players \> controls, *p* \< 0.001; cases \> controls: *p* = 0.02; NS, control volleyball players vs. cases.Yes\
↑ supraspinatus tendon thickness in cases vs non-volleyball player controls Shoulder impingement syndromePark (2007) \[[@CR70]\]Difference in mean skin temperature btwn sh sides in 5 ROIs\
Difference in mean skin temperature btwn sh sides\
anteromedial ROI: cases \> controls, *p* = 0.004.\
anterolateral: cases \> controls, *p* = 0.001.\
posteromedial: cases \> controls, *p* = 0.013.\
posterolateral: cases \> controls, *p* = 0.030.\
lateral: cases \> controls, *p* = 0.039.Yes\
↑ difference in mean skin temperature btwn sides in all 5 ROIs in cases Shoulder pain w. rotator cuff disease (multiple diagnoses)Kalra (2010) \[[@CR40]\]AHD\
No group effects at rest (*p* = 0.43) or 45 degrees abduction (*p* = 0.84). No interaction between group and posture.No Shoulder painO'Sullivan (2012) \[[@CR41]\]Trapezius muscle thickness\
% change in thickness during contraction vs. rest: NS btwn cases & controls in any of the 4 trapezius regions, at 90 degrees or 120 degrees abduction.\
Muscle thickness difference between sides at rest or during contractions in cases: NS in any of the 4 trapezius regions, at 0, 90, or 120 degrees abduction.No Shoulder painRechardt (2010) \[[@CR61]\]Carotid artery intima-media thickness\
Carotid imtima-media thickness, NS in males and females. For each standard deviation increase in carotid IMT, risk of unilateral or bilateral sh pain, OR = 1.4 (95% CI 1.0--1.9) for males 60 + .Perhaps\
↑ carotid artery intima-media thickness increases odds of shoulder pain in males 60+ Shoulder pain (internal impingement pain)Tuite (2007) \[[@CR72]\]Labral length, thick-capsule labrum length, posterior recess angle\
Labral length: cases \> controls, *p* = 0.001. Thick-capsule labrum length: cases \> controls, *p* \< 0.001. Posterior recess angle: cases \> controls, *p* = 0.002. MR arthrogram: greater (dichotomized) glenohumeral internal rotation deficit (GIRD): labral length, thick-capsule labrum length, posterior recess angle, NS.Yes\
↑ labral length in cases\
↑ thick capsule labral length in cases\
↑ posterior recess angle in casesNeck/shoulder disorders and symptoms Neck/shoulder painHallman (2011) \[[@CR80]\]Muscle blood flow (MBF)\
During HGT: MBF cases \< controls (*p* = 0.02 - ipsi; *p* = 0.04 - contra). After HGT: MBF cases \< controls (*p* = 0.001 - ipsi; *p* = 0.003 - contra). During CPT: increase in MBF cases \< controls (*p* = 0.04 - ipsi); NS, contra. After CPT: increase in MBF cases \< controls (*p* \< 0.05 - ipsi); NS, contra.Yes\
↓ MBF in cases during & after HGT in ipsi- and contralateral sides.\
↓ increase in MBF during and after CPT in ipsilateral side. Neck/shoulder painNilsen (2007) \[[@CR42]\]Finger blood flow\
Finger blood flow: baseline, NS. Response to stressful task: group x time (baseline, 0--10 min, 50--60 min) interaction, *p* = 0.02. Post-hoc comparison: controls vs. cases: *p* = 0.35.No Neck/shoulder painShiro (2012) \[[@CR81]\]ΔOHb, ΔHHb, ΔTHb from baseline\
ΔO2Hb: cases \< controls during Relax 3 (*p* \< 0.01) & recovery (*p* \< 0.05). ΔHHb: NS, cases vs. controls. ΔTHb: cases \< controls during Relax 2 & Relax 3 in R trapezius (*p* \< 0.05); cases \< controls: each Relax & recovery in L trapezius (all *p* \< 0.05, except Relax 2 & Relax 3, *p* \< 0.001).Yes\
↓ ΔO2Hb in cases during Relax 3 & recovery.\
↓ ΔTHb in cases during Relax 2 & Relax 3 in R trapezius; during each Relax & recovery in L trapezius Neck/shoulder painStrøm (2009) \[[@CR43]\]Muscle blood flow\
At start of work task: cases vs controls, NS difference in blood flow increase in either active or contralateral trapezius. Blood flow during 15 min of recovery in active & contralateral trapezius: cases \> controls (*p* = 0.05).No Neck/shoulder painTakiguchi (2010) \[[@CR79]\]Minimal & maximal standardized uptake values (SUV) of \[18F\]fluorodeoxyglucose (18F--FDG)\
Trapezius: mean SUVmax, mean SUVmin: cases \< controls, *p* \< 0.0001. Presence/absence of neck/shoulder pain and mean SUVmax (R2 = 0.16, *p* \< 0.0001), and for SUVmin(R2 = 0.26, *p* \< 0.0001), after adjusting for age, gender, smoking status, and diabetes.\
Gluteus maximus: mean SUVmax, mean SUVmin: NS, cases vs. controls mean. Presence/absence of neck/shoulder pain and mean SUVmax or SUVmin, NS.Yes Cervicobrachial pain syndromeLarsson (1998) \[[@CR114]\]Muscle blood flow\
Unilateral pain patients: muscle blood flow: painful \< asymptomatic side, *p* = 0.01; painful \< control, *p* = 0.0009.Yes\
↓ blood flow in painful side in unilateral cases\
↓ blood flow in cases Trapezius myalgiaAcero (1999) \[[@CR74]\]Relative blood volume\
ANOVA - main effect for group, case \< control, during 61--120 s of cold pressor stimulation, *p* = 0.04. All other time points group NS.Yes\
↓ relative blood volume in cases during 61--120 s of cold pressor stimulation. Trapezius myalgiaAndersen (2010) \[[@CR44]\]ΔOHb, ΔHHb, ΔTHb from baseline\
ANOVA - main effect of time for all 3ΔxHb (*p* \< 0.0001), group x time interaction for OHb (*p* \< 0.05). Group effect NS for HHb & THb. Group effect *p*-value for OHb not stated. OHb after exercise increase from baseline: cases \< controls, *p* = 0.05.No Trapezius myalgiaCagnie (2012) \[[@CR75]\]Oxygen saturation, muscle blood flow\
Oxygen saturation: MANOVA - main effects of time, muscle part, and interaction muscle part x group (*p* = 0.049). Post hoc cases \< controls in L & R middle trapezius at all time points *p* = 0.03, except 40 min for R middle trapezius (NS). Blood flow: MANOVA - main effects of time, muscle part, and no interaction muscle part x group. No group effect.Yes\
↓ oxygen saturation in L & R trapezius at all but 1 time point. Trapezius myalgiaFlodgren (2010) \[[@CR76]\]Muscle oxygenation\
Muscle oxygenation percentage decreased during work (*P* = 0.02), and returned to baseline during recovery.Perhaps\
No control subjects were included in this study. Authors conclude normal response in these cases when comparing them to a previous similar study with normal subjects (see Flodgren (2005)). Trapezius myalgiaPeolsson (2008) \[[@CR45]\]Strain rate, strain rate RMS - before provocation, after provocation, difference after - before\
NS cases vs. controls: strain rate, strain rate RMS - before provocation, after provocation, difference after - before. After factor analysis with strain rate and strain variables (not velocity variables), followed by clustering, distribution of cases and controls differed, *p* = 0.05. Examination of factors indicated that post-provocation \-- most cases have lower levels of strain rate & strain after pain provocation compared with most controls.No Trapezius myalgiaSjøgaard (2010) \[[@CR77]\]ΔOHb, ΔHHb, ΔTHb from baseline\
Cases: OHb 35 min after start of peg board task \< baseline, *p* \< 0.05. Controls: OHb not different from baseline. Other OHb, HHb, and THb similar results for cases and controls.Yes\
↓ OHb (vs. baseline) 35 min after start of peg board task in cases, but no change in controls.^a^: result significant in 1 of 2 radiologists

### Neck pain (10 studies) {#Sec11}

Ten studies examined neck pain \[[@CR37], [@CR38], [@CR46]--[@CR53]\]. Decreased muscle dimensions were observed in cases in the cervical multifidus during rest \[[@CR47]\]. In Rahnama et al. \[[@CR52]\], no difference in multifidus muscle thickness was observed during baseline, but there was a smaller increase in cases than in controls in muscle thickness from baseline values during isometric maximum voluntary contraction (MVC). An increased muscle shape ratio (ratio between lateral and anterior-posterior dimensions) was seen in the multifidus of cases \[[@CR47]\]. Reduced muscle dimensions were also observed in the longus colli \[[@CR48], [@CR49]\], and in the semispinalis capitis on cases' painful side \[[@CR50]\]. Dorsal neck muscle thickness change from rest to MVC was different in neck pain cases than in controls, with a tendency toward increased semispinalis capitis thickness in controls, and increased semispinalis cervicis thickness in cases \[[@CR53]\]. There was no difference in subcutaneous tissue thickness above the sternocleidomastoid or anterior scalene muscles \[[@CR38]\].

Greater serratus anterior muscle activity, measured using fMRI, was observed at thoracic vertebral level 6 in cases \[[@CR51]\]. However, less longus colli recruitment, measured by muscle thickness, was found at the greatest flexion angle during incremental nodding \[[@CR49]\]. Elliott et al. \[[@CR46]\] detected less fat infiltration in neck extensors in neck pain vs. whiplash patients. No difference in trapezius skin temperature, or temperature asymmetry between the left and right trapezii was observed in neck pain vs. controls \[[@CR37]\].

### Rotator cuff tear (11 studies) {#Sec12}

Eleven studies investigated rotator cuff tears \[[@CR33]--[@CR36], [@CR39], [@CR54]--[@CR59]\]. Decreased supraspinatus vascularity or blood flow was observed in two studies \[[@CR55], [@CR58]\], and reduced supraspinatus functional capillary density in another \[[@CR54]\]. In patients with unilateral rotator cuff tears with night pain, increased peak systolic velocity and decreased resistance index in the anterior humeral circumflex artery was observed in the symptomatic side in comparison to the asymptomatic side \[[@CR59]\].

Initially asymptomatic full-thickness rotator cuff tears were examined in two unique longitudinal cohorts. Increased tear dimension and tear progression rate was found in asymptomatic rotator cuff tears that became symptomatic versus those that remained asymptomatic \[[@CR33]\]. In this same cohort, Keener et al. \[[@CR34]\] found an increased tear enlargement risk in asymptomatic full-thickness tears and in asymptomatic partial-thickness tears versus those with rotator cuff disease, but no tear. In the other longitudinal study, greater rotator cuff tear size was observed in the anteroposterior plane in tears that became symptomatic at 3-year follow-up, although there was no difference in the tear size at baseline \[[@CR36]\]. No such increase was observed in the other planes examined. In a cross-sectional study, there was no difference between symptomatic and asymptomatic rotator cuff tears in subacromial-subdeltoid bursal fluid amount, proportion of full- or partial-thickness tears, or tear size \[[@CR39]\].

Concommitant to rotator cuff tears, increased dimensions been observed in particular anatomical structures. Greater rotator cable (a fibrous band spanning the insertions of the supraspinatus and infraspinatus) width and thickness were observed in those with full-thickness rotator cuff tears than in healthy subjects \[[@CR57]\]. In full-thickness rotator cuff tears, the biceps long tendon (BLT) showed increased thickness and cross-sectional area, and decreased BLT flattening ratio (width/thickness) in comparison to controls \[[@CR56]\]. In the first longitudinal study referred to above, greater rotator cuff tear width at baseline was observed in those with anterior supraspinatus cable disruption vs. those without such disruption \[[@CR35]\]. However, no difference in tear width enlargement percentage was observed in a minimum of 2 years later.

### Rotator cuff tendinitis (5 studies) {#Sec13}

Five studies examined rotator cuff tendinitis \[[@CR57], [@CR60]--[@CR63]\]. Decreased subacromial distance and humerus diameter \[[@CR60]\] were observed in cases. Joensen et al. \[[@CR62]\] found increased supraspinatus tendon thickness in cases' symptomatic side, while Arend et al. \[[@CR63]\] observed a greater maximal supraspinatus tendon thickness in cases. Greater rotator cable width was observed in rotator cuff tendinosis than in healthy subjects \[[@CR57]\]. No difference in carotid artery intima-media thickness was seen in rotator cuff tendinitis vs. controls \[[@CR61]\].

### Adhesive Capsulitis (4 studies) {#Sec14}

Four studies examined adhesive capsulitis (frozen shoulder) \[[@CR64]--[@CR67]\]. Increased coracohumeral ligament \[[@CR64], [@CR66]\], articular capsule \[[@CR66]\], and axillary recess joint capsule thicknesses \[[@CR65], [@CR67]\] were observed in cases. Increased axillary recess and rotator interval contrast enhancement, along with axillary recess thickening were observed \[[@CR65]\].

### Shoulder impingement syndrome (5 studies) {#Sec15}

Five studies investigated shoulder impingement syndrome \[[@CR58], [@CR68]--[@CR71]\]. Increased supraspinatus tendon thickness was observed \[[@CR69]\]. Decreased acromiohumeral distance (i.e., subacromial distance) was found in one study \[[@CR68]\], but not in another \[[@CR69]\]. Park et al. \[[@CR70]\] found a difference in mean skin temperature between sides (in unilateral shoulder impingement syndrome). Decreased overall supraspinatus blood flow was observed in cases, with less blood flow in specifically in the medial portions of the supraspinatus \[[@CR58]\]. Increased subacromial-subdeltoid bursal thickness was observed in one imaging view in cases \[[@CR71]\].

### Shoulder pain (4 studies) {#Sec16}

Four studies examined shoulder pain \[[@CR40], [@CR41], [@CR61], [@CR72]\]. As the diagnoses were non-specific, we were unable to place them into one of the other more specific categories. Tuite et al. \[[@CR72]\] saw an increased labral length, thick capsule labral length and posterior recess angle in cases. No difference was seen in acromiohumeral distance (AHD) between cases and controls at rest or at 45 degrees abduction \[[@CR40]\]. Neither was any difference observed between groups in percent change in trapezius muscle thickness between rest and during muscle contraction with shoulder abduction \[[@CR41]\]. Rechardt et al. \[[@CR61]\] saw increased carotid artery intima-media thickness in males 60+ with shoulder pain, but not in females or in younger cases.

### Trapezius myalgia, cervicobrachial syndrome and other neck/shoulder pain (12 studies) {#Sec17}

Seven studies examined trapezius myalgia and cervicobrachial syndrome, in which muscle hemodynamics, muscle oxygenation or muscle velocity biomarkers were assessed in the trapezius \[[@CR44], [@CR45], [@CR73]--[@CR77]\]. Decreased muscle blood flow was observed in cases versus controls and on the painful side in unilateral cases \[[@CR78]\]. A decrease was found in muscle relative blood volume during cold pressor stimulation \[[@CR74]\], and oxygen saturation was reduced at baseline and in response to typing \[[@CR75]\]. In response to an upper extremity physical task, decreased oxygenated hemoglobin (compared to baseline) was observed in the trapezius in cases, but not controls \[[@CR77]\]. No difference in change in trapezius blood flow, or in oxygenated or deoxygenated hemoglobin in response to ergometer exercise was found \[[@CR44]\]. Lastly, there was no change in trapezius strain rate/strain rate RMS, a muscle velocity measure, between cases and controls in response to a provocative upper extremity exercise \[[@CR45]\].

Five studies examined neck/shoulder pain \[[@CR42], [@CR43], [@CR79]--[@CR81]\]. Decreased trapezius blood flow was seen during and after hand grip and cold pressor tests \[[@CR80]\]. Decreased trapezius oxygenated hemoglobin and relative blood volume was observed in response to isometric trapezius contractions \[[@CR81]\], but no difference in trapezius blood flow was found in response to a computer work task \[[@CR43]\]. Nilsen et al. \[[@CR42]\] saw no decrease in finger blood flow in response to a stressful task. Minimal and maximal standardized uptake values of \[18F\]fluorodeoxyglucose (18F--FDG), glucose metabolism indicator evaluated by PET/CT were lower in trapezii of cases versus controls, but no difference was observed in the control gluteus maximus, even after adjusting for age, gender, smoking status and diabetes \[[@CR79]\].

In summary, a) neck muscle size appeared to be decreased in neck pain, and b) reduced blood flow, relative blood volume and reduced oxygen saturation was observed in the trapezius at rest and in response to upper extremity tasks with myalgia and neck/shoulder pain.

Are there quantitative imaging biomarkers associated with the severity of neck and shoulder MSDs? {#Sec18}
-------------------------------------------------------------------------------------------------

Five of eight studies demonstrated a relationship between MSD severity and quantitative imaging biomarkers (Table [2](#Tab2){ref-type="table"}). Four studies investigated a quantitative imaging biomarker in relation to a severity score or disease stage assessment determined during a physical examination. Neck Disability Index (NDI) was negatively correlated with longus colli cross-sectional area (CSA) and anterior-posterior distance in neck pain \[[@CR48]\]. No correlation was observed between NDI and trapezius skin temperature \[[@CR37]\] or with fat levels in cervical extensor muscles \[[@CR46]\]. In rotator cuff tears or rotator cuff disease, American Shoulder and Elbow Score (ASES) was significantly decreased with advancing tear type, and with incident pain in the asymptomatic shoulder \[[@CR34]\]. Simple shoulder test score (SST) was similarly reduced.Table 2Are there quantitative imaging biomarkers associated with the severity of neck and shoulder MSDs?MSD Classification or diagnosis\
Author(s)BiomarkerSeverity measure\
mean & range if availableSymptom duration\
(mean & SD if available)Major results (association between biomarker & disease)ConclusionNeck disorders and symptoms Neck pain\
 Dibai Filho (2012) \[[@CR37]\]Skin temperatureNDI\
Cases: 8.33 (SD = 2.65) Controls: 2.27 (SD = 1.27)UnknownCorrelation NDI and skin temperature in right versus left trapezius; thermal asymmetry: NS.No Neck pain\
 Elliott (2008) \[[@CR46]\]Fat index indicating fatty infiltration (relative fat)NDI\
Cases: 21.9 (SD = 7.5) Controls: 45.5 (SD = 15.9)Cases: 33.7 (20.6) mo Controls: 20.3 (9.6) moWithin groups there was no association between NDI and fat levels; total upper fat, *p* = 0.15; total fat, *p* = 0.94. (No description of total vs upper fat in paper)No Neck pain\
 Javanshir (2011) \[[@CR48]\]Longus colli muscle CSA, APD, LD, and LD/APDNDI\
33 (SD = 0.5)\
VAS pain intensity\
5.1 (SD = 0.8)≥ 3 mo^a^NDI and CSA: rho = −0.45, *p* = 0.05, dominant side; rho = −0.48, *p* = 0.03, non-dominant side.\
NDI and APD: rho = −0.49, *p* = 0.03, dominant side; rho = −0.45, *p* = 0.05 non-dominant side.\
NDI and LD or shape ratio, NS.\
VAS and CSA, APD, LD or shape ratio, NS.YesShoulder disorders and symptoms Rotator cuff tear (partial & full) or rotator cuff disease\
 Keener (2015) \[[@CR34]\]Rotator cuff tear enlargement (see paper for definition), shoulder painASES score - American Shoulder & Elbow\
Cases: 98.3 (IRQ = 10)\
Controls: 100(IQR = 0)\
Surgeons SST score - simple shoulder test (score normalized to 100)\
Cases: 91.7 (IQR = 33)\
Controls: 100(IQR = 0)\
VAS pain intensityCases & controls: 1.0 (IQR = 0)UnknownASES: smaller w. advancing tear type, *p* \< 0.05; median decreased by 31.9 points w. new pain, *p* \< 0.05.\
SST: smaller w. advancing tear type, *p* \< 0.05; median decreased by 14.8 points w. new pain, *p* \< 0.05.\
VAS: NS. w. advancing tear type; median increased by 3 points w. new pain, *p* \< 0.05.Yes Shoulder impingement syndrome\
 Park (2007) \[[@CR70]\]Difference in mean skin temperature btwn shoulder sidesVAS pain intensity\
6.6 (5.5--9)22.6 (SD = 40.4) moNS differences btwn normal, hypothermic, and hyperthermic cases for VAS (all cases in this analysis, hypothermic defined as abnormally low temperature in involved side vs uninvolved side, hyperthermic defined as opposite of hypothermic).NoNeck/shoulder disorders and symptoms Neck/shoulder pain\
 Nilsen (2007) \[[@CR42]\]Finger skin blood flowVAS pain intensity: maximal pain response, shoulder pain response, neck pain response\
Maximal pain response:\
Cases: 25 (SD = 20.0)\
Controls: 15 (SD = 16.1)\
Shoulder pain response:\
Cases: 17 (SD = 16.9)\
Controls: 10 (SD = 12.6)\
Neck pain response:\
Cases: 20 (SD = 20.3)\
Controls: 9 (SD = 11.1)\> 3 mo ^a^Maximal pain response: correlation w. finger skin blood flow response during first 10 min of the stressful task in cases, (rho = 0.52, *p* = 0.004), NS in controls (rho = 0.06, *p* = 0.71.Yes Neck/shoulder pain\
 Strøm (2009) \[[@CR43]\]Blood flowComplaint severity score: neck pain, shoulder pain, musculoskeletal complaint severity index (MCI; mean of 7 pain items). 0 = no complaint; 12 = severe complaint. VAS during experiment: pain intensity and general tension\
Median (range) cases: neck pain 3 (1--12), shoulder pain 4 (0--12), MCI 2.5 (0.3--4.1) controls: neck pain 0 (0--6), shoulder pain 0 (0--6), MCI 0.5 (0--2.1) These scores are a composite measure of intensity x duration during the 4 weeks preceding the experiment.3 subjects (2 women) reported having had shoulder and neck pain for less than 12 months, 13 (7 women) for 1--years, three (all men) for 5--10 years, and five (all women) for more than 10 years.Cases: correlation between pain VAS and blood flow in active trapezius at end of work task (90 min): rho = 0.47, *p* = 0.03.\
No correlation at 15 or 45 min into work task, *p* \> 0.05. Controls: no correlation at 15, 45, or 90 min into work task, *p* ≥ 0.05.\
Cases: correlation between pain VAS and blood flow in contralateral trapezius at end of work task (90 min): rho = −0.53, *p* \< 0.01.\
No correlation at 15 or 45 min into work task, *p* \> 0.05. Controls: similar direction of results, no rho or *p*-values supplied.Yes Neck/shoulder pain\
 Takiguchi (2010) \[[@CR79]\]Minimal & maximal standardized uptake values (SUV) of \[18F\]fluorodeoxyglucose (18F--FDG)VAS\> 6 mo, with pain at least 1×/mo^a^Trapezius: mean SUVs & pain VAS (SUVmax: *r* = −0.603, *p* \< 0.0001; SUVmin: *r* = −0.405, *p* \< 0.0001).\
Gluteus maximus: mean SUVs & pain VAS, NS.Yes^a^: inclusion criteria

Six of eight studies solicited pain ratings from participants through a VAS or other means. Three neck/shoulder pain studies investigated pain severity. In Takiguchi et al. \[[@CR79]\], minimal and maximal standardized 18F--FDG uptake values, a glucose metabolism measure, were negatively correlated with VAS pain. In one study, maximal pain response was correlated with finger skin blood flow during the first 10 min of a mentally stressful task in cases, but not controls \[[@CR42]\]. In another study, in cases (but not controls) pain and blood flow was positively correlated in the active trapezius, and negatively correlated in the contralateral trapezius at the end of a 90 min computer task \[[@CR43]\]. No association was observed between pain rating and longus colli CSA, anterior-posterior distance, or other quantitative imaging parameters examined \[[@CR48]\]. Neither was VAS pain related to mean skin temperature differences in shoulder impingement syndrome \[[@CR70]\].

In summary, very few studies reviewed found associations between quantitative imaging biomarkers and neck and shoulder MSD severity. As might be inferred from results to our first research question, functional impairment in neck pain may be associated with reduced longus colli dimensions. Functional impairment in rotator cuff disease in an asymptomatic shoulder may be correlated with increasing tear type and incident shoulder pain. In neck/shoulder syndromes, increased pain may be associated with reduced glucose metabolism and increased blood flow in the active trapezius in response to a computer task.

Discussion {#Sec19}
==========

In this study we have summarized the current state of quantitative medical imaging marker research in neck and shoulder MSDs by conducting a comprehensive systematic review. A critical approach was used to synthesize results for the two research questions: 1) are there quantitative medical imaging markers associated with the presence of neck and shoulder MSDs, and 2) are there quantitative medical imaging markers associated with the severity of neck and shoulder MSDs? Within the studies of sufficient quality, we found associations between quantitative medical imaging biomarkers and neck and shoulder MSDs, and were able to identify several commonalities.

Evidence was found for the following quantitative imaging biomarkers: With respect to referents, decreased neck muscle size was observed in cases with neck pain \[[@CR47]--[@CR50], [@CR52]\]. Reduced trapezius blood flow and relative blood volume \[[@CR73], [@CR74], [@CR80], [@CR81]\] and oxygen saturation at rest and in response to upper extremity tasks \[[@CR75], [@CR77], [@CR81]\] occurred with trapezius myalgia and neck/shoulder pain. Lastly, reduced blood flow and altered vascular parameters were observed in rotator cuff tears \[[@CR54], [@CR55], [@CR58], [@CR59]\].

In contrast to the first research question, associations between biomarkers and the severity of neck and shoulder MSDs were observed in only a few studies. Most notably, minimal and maximal standardized 18F--FDG uptake values, a biomarker of trapezius metabolism in neck/shoulder pain, were inversely correlated with pain, indicating reduced muscle metabolism in this condition. However, this was found in only one study \[[@CR79]\]. The small sample size resulting in reduced ranges of severity measures in many studies examining neck and shoulder MSD severity may have hampered the feasibility of detecting statistically significant results for our second research question.

A possible explanation for the decreased size of deep neck muscles in neck pain cases advanced by several articles \[[@CR47]--[@CR50]\] is the development of muscle atrophy due to a long term reduction in muscle activity through either pain or reflex inhibition. This explanation is consistent with a smaller change in multifidus muscle thickness during MVC from rest in those with neck pain in comparison to control subjects \[[@CR52]\]. In another study, cases and controls showed different patterns of muscle thickness alterations during MVC when compared with rest \[[@CR53]\]. A possible mechanism for activity changes during muscle pain is the redistribution of activity from painful muscles or painful areas to adjacent or synergistic muscles, as described in the pain adaptation model \[[@CR82]\]. Subjects with neck pain showed reduction in deep neck muscle activity in the longus colli \[[@CR49]\]. This was corroborated by prior studies showing reduced strength and endurance during neck flexion tests in subject with neck pain \[[@CR83], [@CR84]\]. However, causal relationships cannot be deduced due to the cross-sectional design of sufficient quality studies.

The pathophysiology associated with reduced blood flow, relative blood volume and oxygen saturation with trapezius myalgia and neck/shoulder pain is not clear. Decreased oxygenation as presented by several studies \[[@CR75], [@CR77]\] may be related to a reduction in oxygen delivery to the muscle or to increased muscle oxygen consumption. Previous studies using muscle microdialysis found increased pyruvate and lactate, metabolites related to increased anaerobic energy production, in painful trapezius muscles \[[@CR77], [@CR85]\]. Findings of reduced trapezius muscle blood flow in response to physical load \[[@CR73], [@CR80], [@CR81]\] or pain induced during an experiment \[[@CR74], [@CR80]\] does not oppose the hypothesis of reduced oxygen delivery. Reduced blood flow may be attributed to an imbalance between vasoconstriction and dilatation in muscle arterioles \[[@CR86]\]. This imbalance could be due to aberrant activation in the sympathetic nervous system or downregulation of adrenoreceptors in the arteriole epithelium in patients with MSDs \[[@CR87]\]. Indeed, in some sufficient quality studies in this review, patients with MSDs show aberrant sympathetic activity compared to asymptomatic controls \[[@CR75], [@CR77], [@CR80]\], although adrenoreceptor expression was not investigated. Together, the reduction in blood flow and oxygen saturation may facilitate the production of muscle metabolites like lactate, which are known to influence muscle nociceptor activity.

Limitations of the review {#Sec20}
-------------------------

Other techniques besides imaging are available for measuring some of the functional and morphological features or processes addressed in this review. However, these other methods for assessing biomarkers were beyond the scope of the present review. For instance, our inclusion criteria allowed for articles on photoplethysmography to measure blood pressure, but not strain-gauge plethysmography. Although the term "plethysmography" was part of our search string, no papers were found that utilized strain-gauge plethysmography in neck or shoulder MSDs. Studies using plain x-rays to the exclusion of other imaging modalities were excluded. Plain radiographs are best utilized in evaluating osteoarthritis, fractures, dislocations and other bone abnormalities, and are not routinely indicated in soft tissue MSDs \[[@CR23]--[@CR26]\]. However, we may have missed some biomarkers that could be of interest such as calcifications, soft tissue swelling, or acromial abnormalities including variant acromial morphology and acromial spurs.

Methodological limitations in the articles reviewed {#Sec21}
---------------------------------------------------

### Selection bias - response rate {#Sec22}

The response rate to participate could be ascertained in only 15 (31%) of the 49 sufficient quality studies. Without response rates, selection bias cannot be adequately assessed. Hence, it is unknown if the cases and controls represent the underlying population, or to what extent they may be comparable. We recommend including response rates for both cases and controls in future quantitative imaging studies.

### Confounding {#Sec23}

Approximately half of the reviewed sufficient quality studies controlled for potential confounders, either through restriction of study subjects (e.g., by age or gender) or through adjustment in the statistical analysis. With respect to the quantitative imaging parameters reviewed here, muscle oxygenation, including in the trapezius, was found to be greater in males than females in many studies \[[@CR88]--[@CR91]\]. However, gender had no influence on erector spinae oxygenation in a sustained trunk extension test \[[@CR92]\]. This latter study also found no difference in relative blood volume with respect to gender. But, literature is sparse in this area. Muscle oxygenation and blood volume responses in limb muscles are significantly influenced by both age \[[@CR93]\] and level of exercise training \[[@CR94]\], yet no study has looked at the effects on shoulder and neck muscles.

Trapezius muscle size is greater in males than females \[[@CR91]\]. In a biopsy study, Lindman et al. \[[@CR95]\] found that female trapezius muscle fibers have smaller cross-sectional areas than males, and more type II fibers. Neck muscle size may also differ by gender. Zheng et al. \[[@CR96]\] found a greater total neck muscle volume in males versus females. However, the proportion of each muscle volume examined in comparison to total neck muscle volume was similar between genders, except for the sternocleidomastoid, longus capitis, and obliqus capitis inferior. Deep neck posterior muscles and semispinalis capitis cross-sectional areas were larger in males than females, but not after adjusting for body weight \[[@CR97]\]. In that study, muscle shape ratio did not differ by gender. Nor were there any differences in muscle dimension by age.

Although several studies suggested that reduced vascularity in the supraspinatus tendon may be associated with rotator cuff tears, two of these studies used much younger controls than cases \[[@CR55], [@CR58]\] (see Additional file [7](#MOESM7){ref-type="media"}). Due to the design of these studies, it is difficult to determine whether the results were due to age or to pathology. Rudzki et al. \[[@CR98]\] found reduced blood flow in the supraspinatus tendon in those over 40 years in their study of asymptomatic rotator cuff tears, which roughly corresponds to the differentiating age between the two groups in the above studies.

The above findings suggest that (minimally) age, gender, exercise frequency, and BMI should be collected from study subjects and controlled for, either during analysis or through selection.

### Directions for future research {#Sec24}

Despite the similarity of symptoms in neck and neck/shoulder disorders, there is a marked difference in the imaging metrics obtained in studies with these two symptom designations. Muscle dimensions have been researched in neck pain, but not in trapezius myalgia and other neck/shoulder disorders. Conversely, muscle oxygenation and relative blood volume have been explored in the trapezius, but not in other neck muscles. Future research should examine muscle dimensions in the trapezius, and muscle oxygenation and relative blood volume in other muscles.

The research on muscle dimension, oxygenation and relative blood volume has been conducted in subjects with different MSD labels, i.e., in neck pain, trapezius myalgia and neck/shoulder pain. Here, we used the diagnosis or syndrome name presented in the articles. These diagnoses or syndrome names are based on the painful region. However, the division between neck and shoulder is not clear. For example, when considering functional anatomy, the neck and upper trapezius could be considered as the same region thus rendering definitions of neck and neck/shoulder regions arbitrary. Furthermore, there are suggestions of a possible common pathophysiological mechanism in these syndromes \[[@CR99]\].

As mentioned previously, a majority of shoulder studies were conducted in older populations (at least one analysis group with mean age ≥ 50 years), whereas the neck and neck/shoulder studies were conducted in younger populations (mean age \< 50 years). This could be due partially to the average age at onset of these disorders. However, given the potential for a possible spectrum effect \[[@CR100]\], it would be of interest to study a broader range of ages.

Only 12 of the 49 sufficient quality studies in this review listed the duration of symptoms in patients (range: 9.1--114 months), all of which durations are chronic by definition \[[@CR36], [@CR38], [@CR40], [@CR41], [@CR46], [@CR47], [@CR64], [@CR66], [@CR68], [@CR70], [@CR73], [@CR76], [@CR80]\]. One review has determined that blood flow increases to the site of rotator cuff small tears, but that decreased vascularity is observed as tear size increases and the healing response fails \[[@CR101]\]. This suggests that varying results in vascularity in the rotator cuff tendons may be influenced by symptom duration. In view of pathophysiological mechanism research, we recommend that quantitative imaging biomarkers be investigated in MSD patients with shorter symptom durations. We further recommend that quantitative imaging biomarker study be report the range of symptoms and their duration.

Although focused on computed tomography imaging methods, animal models would suggest that different quantitative imaging biomarkers and findings are present at different MSD stages \[[@CR102]--[@CR105]\]. In humans, various quantitative imaging biomarkers reflective of underlying musculoskeletal changes are valid at different stages of disease. For instance, the AHD decrease is a late stage phenomenon. It is detectable in large chronic full-thickness rotator cuff tears, but not in earlier stages of rotator cuff disease \[[@CR106]\]. The question of which imaging modality best captures the particular biomarker under consideration is beyond the scope of this review. Determining the most appropriate imaging modality for a given quantitative imaging biomarker is an essential area for future research.

### Heterogeneity -- other considerations {#Sec25}

Quantitative imaging has the potential to be unbiased and precise, particularly in comparison to ordinal scales such as the Bigliani classification \[[@CR107]\] sometimes used in shoulder impingement syndrome. As with all types of biomarkers, optimally, a complete analytical evaluation should be conducted for each quantitative imaging biomarker under consideration. This evaluation should include determination of limit of detection, limit of quantification, reference values in normal subjects, as well as assessing the reliability and validity of any such biomarker \[[@CR108]\]. There are unique considerations for quantitative imaging. Sources of variability include the instrument/acquisition system, and the image measurement algorithm, as well as the patient \[[@CR109]\]. For instance, patient motion may affect the performance of the imaging acquisition system \[[@CR110]\], and image processing software may include a number of steps, each of which requires validation \[[@CR108]\]. See Raunig et al. \[[@CR109]\] for a thorough review of statistical methods for assessing technical performance in quantitative imaging. These technical considerations must be addressed prior to validating the clinical utility of any suggested quantitative imaging biomarker \[[@CR108], [@CR109]\].

Recommendations {#Sec26}
---------------

Below are our brief recommendations for future quantitative imaging biomarker research:Report the response rate for all analysis groups.Carefully consider and report potential confounders, gather information on these factors from study subjects, and potentially control for them through exclusion or through adjustment in the statistical analysis.Report symptom duration and/or severity in study subjects.Clearly describe MSD case definition criteria, including a description of localization of symptoms.Prioritize quantitative imaging biomarker studies that are longitudinal.

Conclusions {#Sec27}
===========

Based on our comprehensive review, there is limited evidence of an association between quantitative medical imaging biomarkers and neck and shoulder MSDs. The most consistent studies suggest that deep neck muscle size holds promise as a biomarker for neck pain, and that trapezius blood flow, relative blood volume, and muscle oxygenation are worthy of consideration as biomarkers for trapezius myalgia and neck/shoulder pain. Further research is warranted. In the meantime, clinicians may find value in our findings. For instance, radiologists may wish to adjust imaging scan planes to allow better volumetric analysis, and refine protocols to better characterize blood flow. Some quantitative imaging parameters, e.g., muscle size and blood flow, are not routinely included in radiology reports. It may behoov the clinician to do so. Additionally, epidemiologists may wish to include these biomarkers in cross-sectional and prospective studies of neck and shoulder MSDs. Prospective high quality studies are needed as this discipline moves forward. Future testing should be done with regard to MSD symptom duration and severity. Results should be reported with consideration to the effects of potentially confounding factors (minimally including age, gender, and exercise), and response rates of all analysis groups should be described so that potential selection bias may be assessed.

Additional files
================

 {#Sec28}

Additional file 1:Search terms for musculoskeletal disorders (MSDs) and imaging markers. (PDF 14 kb) Additional file 2:Questions used in the primary screen for exclusion of articles. (PDF 9 kb) Additional file 3:Questions used in the secondary screen for quality assessment. (PDF 13 kb) Additional file 4:PubMed search string. (PDF 5 kb) Additional file 5:Data extraction items. (PDF 9 kb) Additional file 6:Quality scores for each of the reviewed papers in the primary screen, including the papers of sufficient quality (≥70%) and insufficient quality (\< 70%) \[[@CR114]--[@CR159]\]. (DOCX 177 kb) Additional file 7:Overview with descriptive information of included studies, by anatomical region of the disorder. (DOCX 112 kb)

18F--FDG

:   \[18F\]fluorodeoxyglucose (Glucose analog where one hydoxylgroup has been replaced with a radioacitve fluorine-18 isotope, an indicator of tissue glucose uptake in PET)

ADP

:   Anterior-posterior dimension

AHCA

:   Anterior humeral circumflex artery

AHD

:   Acromiohumeral distance

ANOVA

:   Analysis of Variance

AS

:   Anterior scalene

ASES

:   American Shoulder & Elbow Score (A validated instrument to assess shoulder pain and function \[[@CR111]\])

Assoc.

:   Associated

BA

:   Brachial artery

BLT

:   Biceps long tendon

BMI

:   Body mass index (A measure of body fat based on height and weight)

C3-C6

:   Cervical vertebrae

CCFT

:   Craniocervical flexion test

CHL

:   Coracohumeral ligament

CI

:   Confidence interval

CPT

:   Cold pressor test (A cardiovascular test involving immersion of the dominant hand up to the wrist for 1--3 min in cold water)

CSA

:   Cross - sectional area

HGT

:   Static hand grip test (A test in which the subject presses a dynamometer with their dominant hand \[[@CR80]\])

HR

:   Hazard ratio

IQR

:   Interquartile range

Lco

:   Longus colli muscle

LD

:   Lateral dimension

LD/ADP

:   Muscle shape ratio (ratio between lateral and anterior-posterior dimensions)

MANOVA

:   Multivariate analysis of variance

MBF

:   Muscle blood flow

MCI

:   Musculoskeletal complaint severity index (Mean value of 7 pain areas \[[@CR43]\])

MR

:   Magnetic resonance

MRI

:   Magnetic Resonance Imaging

MSTT

:   Maximal supraspinatus tendon thickness

MVC

:   Maximum voluntary contraction

NDI

:   Neck Disability Index (A validated instrument to assess disability due to neck pain \[[@CR112]\])

NIRS

:   Near infrared spectroscopy

NS

:   Not significant

OHb

:   Oxygenated hemoglobin

OR

:   Odds ratio

PET/CT

:   Positron-emission tomography/computerized tomography

PSV

:   Peak systolic velocity

RCT

:   Rotator cuff tear

RI

:   Resistance index (RI = (PSV (see above) -- end diastoic velocity)/PSV)

RMS

:   Root mean square

ROI

:   Region of interest

SA

:   Serratus anterior muscle

SCM

:   Sternocleidomastoid muscle

SD

:   Standard deviation

SIS

:   Shoulder impingement syndrome

SST

:   Simple shoulder test score (An instrument to assess shoulder functional disability \[[@CR113]\])

SUV

:   Standardized uptake values (Measurment for quantification in positron-emission tomography)

T6-T10

:   Thoracic vertebrae

TVI

:   Tissue velocity imaging

VAS

:   Visual Analogue Scale

VO2max

:   Maximal oxygen uptake

ΔHHb

:   Change in de-oxygenated hemoglobin (Determined through NIRS, from a baseline value)

ΔOHb

:   Change in oxygenated hemoglobin (Determined through NIRS, from a baseline value)

ΔTHb

:   Change in total hemoglobin, interpreted as relative blood volume (Determined through NIRS, from a baseline value)
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